APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 323 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $517,344 | -74.9% | 13,600 | -39.8% | 0.00% | -75.0% |
| Q2 2023 | $2,058,860 | +73.4% | 22,600 | +25.6% | 0.00% | +100.0% |
| Q1 2023 | $1,187,280 | +58.1% | 18,000 | +63.6% | 0.00% | 0.0% |
| Q3 2022 | $751,000 | -69.9% | 11,000 | -80.1% | 0.00% | 0.0% |
| Q2 2022 | $2,493,000 | +50.7% | 55,140 | +69.4% | 0.00% | +100.0% |
| Q1 2022 | $1,654,000 | +19.1% | 32,550 | +10.9% | 0.00% | 0.0% |
| Q4 2021 | $1,389,000 | -16.2% | 29,350 | +11.9% | 0.00% | 0.0% |
| Q2 2021 | $1,658,000 | +630.4% | 26,240 | +395.1% | 0.00% | – |
| Q1 2021 | $227,000 | -25.1% | 5,300 | 0.0% | 0.00% | – |
| Q4 2020 | $303,000 | -58.4% | 5,300 | -78.0% | 0.00% | -100.0% |
| Q3 2020 | $728,000 | -15.1% | 24,120 | -8.0% | 0.00% | 0.0% |
| Q2 2020 | $857,000 | +13.8% | 26,222 | -6.8% | 0.00% | 0.0% |
| Q1 2020 | $753,000 | -19.6% | 28,122 | -8.1% | 0.00% | 0.0% |
| Q4 2019 | $937,000 | – | 30,604 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 1,526,122 | $29,759,000 | 24.10% |
| Cormorant Asset Management, LP | 3,600,000 | $70,200,000 | 4.74% |
| SECTORAL ASSET MANAGEMENT INC | 1,727,829 | $33,693,000 | 4.05% |
| Hillhouse Capital Management | 2,098,581 | $40,922,000 | 1.71% |
| HHLR ADVISORS, LTD. | 2,579,708 | $50,304,000 | 1.40% |
| CLOUGH CAPITAL PARTNERS L P | 589,734 | $11,500,000 | 1.01% |
| Vivo Capital, LLC | 383,538 | $7,479,000 | 0.75% |
| Opaleye Management Inc. | 115,000 | $2,243,000 | 0.62% |
| Virtus ETF Advisers LLC | 14,338 | $280,000 | 0.60% |
| Eversept Partners, LP | 104,349 | $2,034,806 | 0.59% |